Condition: Recurrent Ovarian Cancer · Folate Receptor-Alpha Positive · Sponsor: AbbVie
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| University of California Los Angeles /ID# 269339 | Los Angeles, California, United States | Recruiting |
| Norton Cancer Institute - St. Matthews /ID# 269070 | Louisville, Kentucky, United States | Completed |
| Holy Cross Hospital - Silver Spring /ID# 269344 | Silver Spring, Maryland, United States | Recruiting |
| Mercy David C. Pratt Cancer Center /ID# 269350 | St Louis, Missouri, United States | Recruiting |
| The Center Of Hope /ID# 269348 | Reno, Nevada, United States | Active Not Recruiting |
| Holy Name Medical Center /ID# 269340 | Teaneck, New Jersey, United States | Recruiting |
| New York Oncology Hematology - Albany Cancer Center /ID# 269345 | Albany, New York, United States | Completed |
| Women'S Cancer Care Associates /ID# 269980 | Albany, New York, United States | Completed |
| Duke Cancer Institute /ID# 269342 | Durham, North Carolina, United States | Recruiting |
| Summa Health /ID# 269349 | Akron, Ohio, United States | Recruiting |
| UT Southwestern Medical Center /ID# 269341 | Dallas, Texas, United States | Recruiting |
| Memorial Hermann Southeast Hospital /ID# 269347 | Houston, Texas, United States | Completed |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06365853